GB9927757D0 - Treatment of autoimmune diseases - Google Patents
Treatment of autoimmune diseasesInfo
- Publication number
- GB9927757D0 GB9927757D0 GBGB9927757.6A GB9927757A GB9927757D0 GB 9927757 D0 GB9927757 D0 GB 9927757D0 GB 9927757 A GB9927757 A GB 9927757A GB 9927757 D0 GB9927757 D0 GB 9927757D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- treatment
- autoimmune diseases
- autoimmune
- diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 208000023275 Autoimmune disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Rehabilitation Therapy (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927757.6A GB9927757D0 (en) | 1999-11-25 | 1999-11-25 | Treatment of autoimmune diseases |
| EP00977741A EP1146902A1 (en) | 1999-11-25 | 2000-11-27 | Treatment of autommune diseases by an agonistic cd40-binding protein |
| PCT/GB2000/004511 WO2001037870A1 (en) | 1999-11-25 | 2000-11-27 | Treatment of autoimmune diseases by an agonistic cd40-binding protein |
| JP2001539484A JP2003514873A (en) | 1999-11-25 | 2000-11-27 | Treatment of autoimmune diseases with active CD40 binding proteins |
| AU15376/01A AU1537601A (en) | 1999-11-25 | 2000-11-27 | Treatment of autoimmune diseases by an agonistic CD40-binding protein |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9927757.6A GB9927757D0 (en) | 1999-11-25 | 1999-11-25 | Treatment of autoimmune diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB9927757D0 true GB9927757D0 (en) | 2000-01-26 |
Family
ID=10865044
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GBGB9927757.6A Ceased GB9927757D0 (en) | 1999-11-25 | 1999-11-25 | Treatment of autoimmune diseases |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1146902A1 (en) |
| JP (1) | JP2003514873A (en) |
| AU (1) | AU1537601A (en) |
| GB (1) | GB9927757D0 (en) |
| WO (1) | WO2001037870A1 (en) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1414483A1 (en) * | 2001-07-31 | 2004-05-06 | Serono Genetics Institute S.A. | Agonists and antagonists of moxifin for the treatment of metabolic disorders |
| AR039067A1 (en) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | ANTIBODIES FOR CD40 |
| AU2002346581A1 (en) * | 2001-11-26 | 2003-06-10 | Chiron Corporation | Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment |
| AU2003230765A1 (en) * | 2002-03-29 | 2003-10-13 | Bayhill Therapeutics, Inc. | Use of statins and other immunomodulatory agents in the treatment of autoimmune disease |
| US20070041971A1 (en) * | 2003-07-07 | 2007-02-22 | Wagner David H | Methods for predicting development of auto-immune diseases and treatment of same |
| GB201006096D0 (en) * | 2010-04-13 | 2010-05-26 | Alligator Bioscience Ab | Novel compositions and uses thereof |
| GB201413665D0 (en) | 2014-07-03 | 2014-09-17 | Transimmune Ag And Yale University | Method for obtaining globally activated monocytes |
| AU2016291817A1 (en) | 2015-07-16 | 2018-02-22 | Biolinerx Ltd. | Compositions and methods for treating cancer |
| SG11201810509PA (en) | 2016-06-20 | 2018-12-28 | Kymab Ltd | Anti-pd-l1 antibodies |
| CA3148890A1 (en) * | 2019-09-11 | 2021-03-18 | Novartis Ag | A method for preventing human virus associated disorders in patients |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661360B2 (en) * | 1991-10-25 | 1995-07-20 | Immunex Corporation | Novel cytokine |
| CZ244399A3 (en) * | 1997-01-10 | 1999-10-13 | Biogen, Inc. | The use of an anti-CD40L compound for the manufacture of a medicament for the treatment of immunological diseases |
-
1999
- 1999-11-25 GB GBGB9927757.6A patent/GB9927757D0/en not_active Ceased
-
2000
- 2000-11-27 WO PCT/GB2000/004511 patent/WO2001037870A1/en not_active Ceased
- 2000-11-27 AU AU15376/01A patent/AU1537601A/en not_active Abandoned
- 2000-11-27 EP EP00977741A patent/EP1146902A1/en not_active Withdrawn
- 2000-11-27 JP JP2001539484A patent/JP2003514873A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001037870A1 (en) | 2001-05-31 |
| EP1146902A1 (en) | 2001-10-24 |
| AU1537601A (en) | 2001-06-04 |
| JP2003514873A (en) | 2003-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL144981A0 (en) | Treatment of autoimmune disease | |
| HUP0200079A3 (en) | Treatment of infertility | |
| AU7434101A (en) | Treatment of bone diseases | |
| HUP0200157A3 (en) | Treatment of infertility | |
| HUP0104963A3 (en) | Compositions for the treatment of skin diseases | |
| PL336760A1 (en) | Treatment of skin diseases | |
| AU3896900A (en) | Treatment of pain | |
| GB9927757D0 (en) | Treatment of autoimmune diseases | |
| PL336579A1 (en) | Treatment of diseases associated with cytokinins | |
| NZ513686A (en) | Treatment of trauma | |
| GB2360453B (en) | Treatment of skin conditions | |
| IL149281A0 (en) | Treatment of cancer | |
| EP1107778A4 (en) | Treatment of disease states | |
| AU1405001A (en) | Treatment of diseases | |
| GB9908059D0 (en) | Diagnosis and treatment of diseases | |
| ZA991783B (en) | Therapeutic treatment for autoimmune diseases. | |
| AU1324002A (en) | Treatment of demyelinating diseases | |
| GB9919565D0 (en) | Treatment of disease | |
| PL351081A1 (en) | Treatment of hiatial hernia | |
| EP1165060A4 (en) | Treatment of gallstones | |
| GB9710054D0 (en) | Treatment of diseases | |
| GB9901310D0 (en) | Methods of treatment | |
| GB9917181D0 (en) | Methods of treatment | |
| IL143568A0 (en) | Treatment of infertility | |
| PL350221A1 (en) | Treatment of infertility |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AT | Applications terminated before publication under section 16(1) |